Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000702976 | SCV000831854 | pathogenic | Hereditary nonpolyposis colorectal neoplasms | 2018-06-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant has been observed in an individual affected with Lynch syndrome (PMID: 20877318). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Tyr678*) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. |
Ambry Genetics | RCV002422583 | SCV002723006 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-05-04 | criteria provided, single submitter | clinical testing | The p.Y678* pathogenic mutation (also known as c.2034T>A), located in coding exon 13 of the MSH2 gene, results from a T to A substitution at nucleotide position 2034. This changes the amino acid from a tyrosine to a stop codon within coding exon 13. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |